Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
01/2010
01/07/2010WO2010001413A2 Sustained release pharmaceutical compositions comprising quetiapine
01/07/2010WO2010001366A1 Piperazines derivatives as proteasome modulators
01/07/2010WO2010001365A1 Nitrogen heterocycle derivatives as proteasome modulators
01/07/2010WO2010001349A1 Rna antagonists targeting hsp27
01/07/2010WO2010001258A2 Inhibition of tumour growth and metastases
01/07/2010WO2010001257A2 Novel solid state forms of laquinimod and its sodium salt
01/07/2010WO2010001220A1 New 1,2,4-triazine derivatives and biological applications thereof
01/07/2010WO2010001185A1 Thieno [2,3-b] pyridine compounds with mglur activity
01/07/2010WO2010001179A2 Calcium ion channel modulators & uses thereof
01/07/2010WO2010001169A2 Chemical compounds 251
01/07/2010WO2010001167A2 Novel process
01/07/2010WO2010001166A1 Thiazole derivatives as gpr 119 modulators
01/07/2010WO2010001126A1 Thiophene derivatives as kinase inhibitors
01/07/2010WO2010001102A2 Method
01/07/2010WO2010001096A2 Treatment
01/07/2010WO2010000978A1 Novel pyrrolo [2,3-a] carbazoles and use thereof as pim kinase inhibitors
01/07/2010WO2010000964A1 Microbiological method for synthesizing cinnamoyl amide derivatives of amino acids
01/07/2010WO2010000943A1 An intrauterine delivery system for contraception
01/07/2010WO2010000906A1 Pharmaceutical composition with glycosaminoglycans and use thereof in the treatment of chronic ulcers
01/07/2010WO2010000905A1 Pharmaceutical composition with glycosaminoglycans and use thereof in the treatment of chronic ulcers
01/07/2010WO2010000904A1 Pharmaceutical composition with glycosaminoglycans and use thereof in the treatment of chronic ulcers
01/07/2010WO2010000900A1 Immunosuppressor based on the interruption of tcr-nck interaction
01/07/2010WO2010000851A2 Methods for modulating angiogenesis via dystrophin dp71
01/07/2010WO2010000817A1 Antitumoral macrolides
01/07/2010WO2010000784A1 Treatment of restenosis
01/07/2010WO2010000763A2 Combination products
01/07/2010WO2010000748A1 5-phenyl-isoxazole-3-carboxamides modulating hsp90 with antitumoral activities
01/07/2010WO2010000704A1 3-(n-heterocyclyl)-pyrrolidinyl-phenyl-oxazolidinones as antibacterial agents
01/07/2010WO2010000703A1 3-cyanopyrrolidinyl-phenyl-oxazolidinones as antibacterial agents
01/07/2010WO2010000686A2 Composition for topical use
01/07/2010WO2010000673A1 N'-nitroxyalkylnicotinamides for the treatment of cardiovascular diseases
01/07/2010WO2010000668A1 A crystalline form of posaconazole
01/07/2010WO2010000661A1 Compounds useful for the prevention or treatment of accomodative asthenopia
01/07/2010WO2010000656A1 Rna antagonist compounds for the inhibition of expression of mitochondrial glycerol-3-phosphate acyltransferase 1 (mtgpat1)
01/07/2010WO2010000633A1 Novel phenylpyrazinones as kinase inhibitors
01/07/2010WO2010000545A1 A process for producing lercanidipine hc1 form v
01/07/2010WO2010000469A2 Crystalline salts of sitagliptin
01/07/2010WO2010000459A1 Cyclopropyl polymerase inhibitors
01/07/2010WO2010000456A1 Substituted 6- (1-piperazinyl) -pyridazines as 5-ht6 receptor antagonists
01/07/2010WO2010000437A1 Antiallergic marine biopolymers
01/07/2010WO2010000429A1 Adenine receptor ligands
01/07/2010WO2010000404A1 Oxazolidinones for the treatment of inflammatory conditions of the gastrointestinal tract
01/07/2010WO2010000401A1 Use of substituted pyridinone carboxylic acid derivates for producing pharmaceuticals for the treatment of dyslipidemia
01/07/2010WO2010000399A1 Use of nifurtimox for treating giardiasis
01/07/2010WO2010000398A1 Nifurtimox for treating diseases caused by trichomonadida
01/07/2010WO2010000396A1 Salts comprising a pyrimidinecarboxylic acid derivative for cosmetic use
01/07/2010WO2010000364A1 Pyrrolopyridinylpyrimidin-2-ylamine derivatives
01/07/2010WO2010000353A1 Sulfonamides with heterocycle and oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals
01/07/2010WO2010000207A1 A natural allicin tablet and preparation method thereof
01/07/2010WO2010000198A1 Benzothiophene alkanol piperazine derivatives and their use as antidepressant
01/07/2010WO2010000073A1 Benzoxazines, benzothiazines, and related compounds having nos inhibitory activity
01/07/2010WO2010000066A1 Diglycidic ether derivative therapeutics and methods for their use
01/07/2010WO2010000050A1 Pharmaceutical compositions of nanoparticles containing active ingredients
01/07/2010WO2010000032A1 Compounds having antiviral properties
01/07/2010WO2010000031A1 Imidazopyrimidinones and uses thereof
01/07/2010WO2010000030A1 Thiazopyrimidinones and uses thereof
01/07/2010WO2010000019A1 Pain-relieving compositions of furoxan no donors and uses thereof
01/07/2010WO2010000013A1 A sulfated polysaccharide compound and the preparation and use thereof
01/07/2010WO2010000011A1 The use of androgens for vascular regeneration and endothelial repair
01/07/2010WO2010000008A1 Thiosemicarbazone compounds and use thereof
01/07/2010WO2009143024A3 Compounds and methods for kinase modulation, and indications therefor
01/07/2010WO2009140626A3 Long term disease modification using immunostimulatory oligonucleotides
01/07/2010WO2009140457A3 Combinations of antioxidants and anti-inflammatory drugs in the of treatment inflammatory bowel disease
01/07/2010WO2009140448A8 Tetrahydrocyclopenta[b]indole androgen receptor modulators
01/07/2010WO2009140408A3 Metal abstraction peptide (map) tag and associated methods
01/07/2010WO2009140383A3 Aptamers that bind to p-selectin and their use as coagulation, thrombotic, inflammatory, and metastatic disease therapeutics
01/07/2010WO2009140204A3 Selective subtype alpha 2 adrenergic agents and methods for use thereof
01/07/2010WO2009140166A3 Oxazolobenzimidazole derivatives
01/07/2010WO2009140128A3 Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
01/07/2010WO2009140105A3 Formulations for cathepsin k inhibitors
01/07/2010WO2009139817A3 Crystalline pharmaceutical and methods of preparation and use thereof
01/07/2010WO2009138796A3 Imidazo [2,1-b] quinazolin-2-one derivatives and their use as platelet anti-aggregative agents
01/07/2010WO2009138758A3 Bis-aryl compounds for use as medicaments
01/07/2010WO2009138734A3 Use of opioid compounds in peripheral pain, wound healing and scar formation
01/07/2010WO2009138195A3 Use of thiophene glycoside derivatives for producing medicaments for treatment of hypertension
01/07/2010WO2009137660A9 Enhancement of drug therapy by mirna
01/07/2010WO2009137462A3 Methods for treating cognitive disorders using inhibitors of histone deacetylase
01/07/2010WO2009137322A3 Processes for the preparation of biphenyl compounds
01/07/2010WO2009137103A3 Anti-cancer/anti-viral compounds and methods of use
01/07/2010WO2009132320A3 Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging
01/07/2010WO2009131954A3 Compounds, compositions and methods comprising oxadiazole derivatives
01/07/2010WO2009131951A3 Compounds, compositions and methods comprising isoxazole derivatives
01/07/2010WO2009131947A3 Compounds, compositions and methods comprising pyridazine derivatives
01/07/2010WO2009131850A3 Pai-1 expression and activity inhibitors for the treatment of ocular disorders
01/07/2010WO2009131687A3 Inhibitors of protein kinases
01/07/2010WO2009129494A3 Alpha and beta adrenergic receptor agonists for treatment of pain and/or inflammation
01/07/2010WO2009129464A3 Method for treating acute pain with a formulated drug depot in combination with a liquid formulation
01/07/2010WO2009129336A3 Penetrating carrier, antifungal composition using the same and method for treatment of dermatophyte infections
01/07/2010WO2009129259A3 Polymorphs of 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n-(1-methylpiperidin-4-yl)-9h-pyrido[2,3-b]indole-7-carboxamide and methods of use therefor
01/07/2010WO2009129155A3 Dexamethasone formulations in a biodegradable material
01/07/2010WO2009126805A3 Therapeutic tarageting of mmps in neutral liposomes
01/07/2010WO2009125433A3 Process for preparation of amine polymer salt
01/07/2010WO2009124723A3 Novel aureothin derivatives
01/07/2010WO2009122431A3 Oral controlled release tablet with reduced burst effect
01/07/2010WO2009121992A3 Use of maslinic acid for the treatment of diseases and the symptoms thereof by means of cox-2 inhibition
01/07/2010WO2009121535A3 Antiproliferative compounds and therapeutic uses thereof
01/07/2010WO2009120954A3 Nicotine immunoconjugates
01/07/2010WO2009120815A9 Therapeutic compositions and methods
01/07/2010WO2009120390A3 Cyclopropanated carbohydrates
01/07/2010WO2009118712A3 Novel dihydroxypyrrolidine derivatives as anti-cancer agents